Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes

To investigate the long-term usefulness of immunosuppressive therapy (IST) for Japanese patients with lower-risk myelodysplastic syndromes, we retrospectively analyzed 29 MDS patients who were treated with cyclosporine A alone or with anti-thymocyte globulin at a single institute in Japan. A total o...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematology 2013-12, Vol.98 (6), p.687-693
Main Authors: Hata, Tomoko, Tsushima, Hideki, Baba, Maki, Imaizumi, Yoshitaka, Taguchi, Jun, Imanishi, Daisuke, Nagai, Kazuhiro, Tomonaga, Masao, Miyazaki, Yasushi
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antilymphocyte Serum - therapeutic use
Biological and medical sciences
Cause of Death
Cyclosporine - therapeutic use
Female
Follow-Up Studies
Hematologic and hematopoietic diseases
Hematology
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Japan
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Myelodysplastic syndromes
Myelodysplastic Syndromes - drug therapy
Myelodysplastic Syndromes - mortality
Oncology
Original Article
Retrospective Studies
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the long-term usefulness of immunosuppressive therapy (IST) for Japanese patients with lower-risk myelodysplastic syndromes, we retrospectively analyzed 29 MDS patients who were treated with cyclosporine A alone or with anti-thymocyte globulin at a single institute in Japan. A total of 58.6 % of patients showed hematological response to IST. Overall survival of all patients was 74.5 % at 5 years and 48.3 % at 10 years. The major adverse event was the elevation of creatinine level (grade 1 and 2). Eleven patients were still on IST at the time of analysis with, at least, some clinical benefits. Pneumonia was the most frequent cause of death (eight of 12 deaths), followed by bleeding (three of 12); most of the patients who died were non-responders. The presence of paroxysmal nocturnal hemoglobinuria–type cells was significantly associated with both response to IST and long-term survival by univariate analysis. The 10-year overall survival of responders (72.2 %) was significantly superior to that of non-responders (15.6 %, P  
ISSN:0925-5710
1865-3774
DOI:10.1007/s12185-013-1468-8